Search

Patients diagnosed with hematology malignancy and solid tumor who underwent chemotherapy, frequently encountered hepatitis B reactivation. Patients with blood cancer, including lymphoma, had higher risk of reactivation compared to those with solid tumor. Steroid and immunosuppressant drugs contained in chemotherapy regimens were responsible for those events. Hepatitis B reactivation during chemotherapy treatment could contribute to acute liver failure and increase mortality. Administration of analog nucleoside therapy in this group of patient prior to the initiation of chemotherapy could prevent reactivation of hepatitis B. A 43 year-old male patient were diagnosed with diffuse large B cell non-Hodgkin lymphoma stadium II BE (oropharynx) under chemotherapy and had hepatitis B. In this evidence based case report, we reported a critical appraisal of the role of lamivudine as preemptive therapy in blood cancer and solid tumor. [ABSTRACT FROM AUTHOR]

Background Chemotherapy, as treatment, may responsible for undesired side effects, such as sarcopenia and chemotherapy toxicity. Based on the previous study, slow muscle mass may increase hematological toxicity and decrease response of chemotherapy effectiveness. The reported data about hematological chemotherapy toxicity and low muscle mass in Indonesian breast cancer patients is very limited thus the aim of this study to find out the prevalence and association between them. Methods This was cross-sectional study, conducted in our general hospital at Tangerang, Indonesia. Muscle mass was measured using Bio Impedance analysis. The first step, Asian Working Group for Sarcopenia (AWGS) criteria is used to count muscle mass cut-off in Indonesian population by height-based muscle mass. AWGS recommends to define low muscle mass as below the mean minus 2 standard deviation. The second step, blood sample from breast cancer patients undergoing chemotherapy were taken consecutively. The cut-off for defining anemia is hemoglobin <12g/dL; leukopenia is leukocyte count <5.000/mm3, and thrombocytopenia is < 150.000/mm3. The Chi Square analysis was used to see the association. Results The first step of the study included 137 young adult women. Cut off point of muscle mass in Indonesian female was 4.781 kg/m2. The second step, a total of 36 breast cancer patients with mean age 48.08±9.73 were included. Anemia was found in 20 (54%) subjects, leukopenia in 2 (5.5%) subjects, thrombocytopenia in 1 (2.7%) subject. In this study, patient with low muscle mass only found in 1 of 37 patients. Conclusion Cut-off muscle mass for Indonesian female is 4.781kg/m2, lower than AWGS standard. There is no statistically significant between low muscle mass and hematological toxicity in breast cancer patient. Further study needs to be evaluated in bigger population to confirm this result. [ABSTRACT FROM AUTHOR]

Background Chemotherapy, which still is the first line for Breast Cancer treatment, plays a significant role in the undesirable side effects including Gastrointestinal Chemotherapy Toxicity, such as Nausea, Vomiting. Even though there are a lot of studies which show adequate Quality of Life (QoL), minimum data is reported in Indonesia on breast cancer patients. The purpose of this study is to assess the QoL in the breast cancer patient in Indonesia influenced by GI chemotherapy toxicity. Method A cross-sectional study was done at the general hospital in Tangerang, Indonesia from October 2018- February 2019. The breast cancer patient who has underwent adjuvant chemotherapy is included in this study and assessed using BR23 questionnaire which assess the functional and symptoms scale of the patient, ranged from 0% (worst function and most symptoms) to 100% (the best function and no symptoms) and National Cancer Institute Common Toxicity Criteria (> 1 consider as toxic). Association between both variables are analysed with Spearmańs correlation using SPSS version 24.0 Result The data was collected from 32 patients with mean age of 47.72 ±9.095. It is found that functional scale mean is 55.47% ± 8.53 and toxicity scale mean is 85.89% ±11.61. 30 patients has experienced no chemotherapy toxicity. The association between Functional QoL and Gastrointestinal Chemotherapy Toxicity is defined as 0.254 with the p -value of 0.161, while the association between Symptoms QoL and Gastrointestinal Chemotherapy Toxicity is defined as - 0.308 with the p -value of 0.08. Conclusion Majority of the patients shows adequate Quality of Life and no experienced any chemotherapy toxicity. the association between QoL and Gastrointestinal Chemotherapy Toxicity is low. Thus, further investigation with greater number of sample is needed to confirm the result. [ABSTRACT FROM AUTHOR]

Background Previous studies have shown that the prevalence of anemia increases following chemotherapy. Anemia is associated with a decline of quality of life in cancer patients. But there is limited study in breast cancer population. The purpose of this study is to evaluate the association of anemia and quality of life in breast cancer patients before chemotherapy. Methods The study was done using a cross-sectional Method in our general hospital in Tangerang, Banten, Indonesia from October 2018-March 2019. Breast cancer patients who are yet to receive chemotherapy are included in this study. A blood sample is taken before chemotherapy for hemoglobin (Hb) level assessment with cut-off <12 mg/dL for anemia, and quality of life is assessed using European Organisation for Research and Treatment of Cancer breast cancer specific-quality of life questionnaire (EORTC QLQ-BR23) which evaluates the functional and symptoms scale of the patient, 0% is the worst function and most symptoms and 100% is the best function and no symptoms. Association of the two variables are analysed with T-test correlation using SPSS version 24.0 Results From 37 breast cancer patients with mean age 48.08±9.736, anemia is found in 20 (54%) subjects. When assessed with QLQ-BR23, mean functional and mean symptoms scale in anemic patient is 54.27%±8.77% and 83.27%±12.77% respectively. Mean functional and mean symptoms scale in normal patient is 55.64%±7.96% and 89.85%±7.86% respectively (p-value=0.064). Conclusion The association of anemia and quality of life in breast cancer patients before chemotherapy is not clinically significant but further study with a larger sample size is needed to confirm this findings. [ABSTRACT FROM AUTHOR]

Background Chemotherapy is still the first line treatment for breast cancer patients. Gastrointestinal chemotoxicity such as nausea and vomiting remain as distressing adverse side effects. However, not many data discussed the impact of these side effect on the performance status of the patients. Thus, the aim of the study is to evaluate the Association of gastroenteric chemotoxicity to the performance status of Breast cancer patients. Method A cross-sectional study was done in our general hospital starting from October 2018 until February 2019. The patients included are those diagnosed with breast cancer and have undergone chemotherapy. Chemotherapy toxicity is assessed using the National cancer institute common toxicity criteria (NCI-CTC) with a cut-off above 1 point. and Eastern Cooperative Oncology Group (ECOG) was used to assess the patient´s performance status. The ECOG has a scoring system (0-5). Which 0 defines as fully active and 5 as dead. The correlation between both variables was analyzed with spearman using SPSS version 24.0 Result Data are collected from 32 patients with mean age 47.72±9.095. Out of the patients, only 6.2% experienced nausea and vomiting. The performance status data showed 46.9% scored 0, 50% scored 1, and only 3.1% scored 2. The association of these chemotoxicity to the patient´s status performance is less significant with r = 0.223, p-value=0.221 Conclusion Chemotoxicity did not occur in most patient. However patients still tends to have restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. The study resulted in minimum coherence and significance from both variables. Therefore further study with a larger sample size should be done. [ABSTRACT FROM AUTHOR]

Background Survival of breast cancer patients who are obese is worse than normal weight or underweight. Gastrointestinal (GI) chemotherapy toxicity is increase in patient with low skeletal mass. Sarcopenia obesity is emerging problem in elderly population, but there is limited data in breast cancer patient. The aim of this study is to evaluate association between Body Mass Index (BMI) and GI chemotherapy toxicity in breast cancer patients. Methods A cross-sectional study was done in our general hospital starting from October 2018 until February 2019. The patients included in this study are those diagnosed with breast cancer and have undergone chemotherapy. Chemotherapy toxicity is assessed using the National Cancer Institute Common Toxicity Criteria (NCI CTC) with a cut off above 1 point and BMI is categorised using WHO Asia pacific criteria measured with cut off less than 18.5 as underweight, 18.5-22.9 as normal range, 23-24.9 as at risk and 25-29.9 as Obese 1. The association between BMI and GI chemotherapy toxicity was analysed with Chi-square using SPSS version 24. Results The data collected from 31 patients with mean age of 47.74±9.245. Mean BMI is 23.9±4.11 with underweight 6.3%, normal 46.9% and overweight 9.4%, pre-obese 34.4%, obese type-1 3.1%. NCI CTC Constipation toxicity score 0 (71%), 1 (22.6%), 2 (6.5%). NCI CTC Diarrhoea score 0 (80.6%), 1 (12.9%), 2 (6.5%). 29 patients were reported with no GI toxicity and 2 patients were reported with GI toxicity. No toxicity was reported in 16 patients with normal BMI and 2 toxicity were reported in 15 obese patients (p-value=0.226). Conclusion The association between obesity and GI chemotherapy toxicity is not clinically significant but further study with a larger sample size is needed to confirm this findings. [ABSTRACT FROM AUTHOR]